Skip to main content

Table 3 Concomitant cardiovascular illnesses and risk factors in the overall population

From: Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial

    Cariporide
  All (n=11 587) Placebo (n=2909) 20 mg (n=2908) 80 mg (n=2887) 120 mg (n=2883)
Median age (years) 66.0 65 66 66 66
Sex (% male) 69.9 70.0 70.2 69.3 69.9
Smoking status (%)      
   Current 22.8 23.7 22.1 23.0 22.5
   Ex smoker 44.7 44.6 45.1 44.4 44.6
   MI at study entry (%) 10.4 10.0 11.1 10.4 10.1
History of (%)      
   Stable angina 24.1 23.8 23.9 23.6 25.0
   Unstable angina 58.8 58.0 59.9 59.4 58.0
   MI 44.5 44.0 45.4 44.6 43.9
   Congestive heart failure 7.7 7.1 8.3 7.4 7.9
   Hypertension 53.1 51.8 53.7 53.3 53.5
   Cerebrovascular disease 6.1 5.4 6.0 6.2 6.7
   Peripheral vascular disease 13.5 12.9 13.9 13.9 13.1
   Cardiac arrhythmia 12.2 11.7 13.0 11.5 12.4
   Hypercholesterolemia 55.0 54.3 55.1 55.9 54.8
   NIDDM 19.7 19.2 20.2 20.5 18.9
   IDDM 7.1 6.1 7.2 7.1 8.0
  1. IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-dependent diabetes mellitus.